File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: One-week antibiotics versus maintenance acid suppression therapy for Helicobacter pylori-associated peptic ulcer bleeding

TitleOne-week antibiotics versus maintenance acid suppression therapy for Helicobacter pylori-associated peptic ulcer bleeding
Authors
Issue Date1997
PublisherSpringer New York LLC. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0163-2116
Citation
Digestive Diseases And Sciences, 1997, v. 42 n. 12, p. 2524-2528 How to Cite?
AbstractBleeding peptic ulcer is the most important cause of upper gastrointestinal bleeding. Our aim was to compare the effect of anti- Helicobacter therapy with maintenance treatment of H 2-receptor antagonist in the prevention of relapses of ulcer and bleeding. Patients with bleeding duodenal or gastric ulcers and H. pylori infection were randomized to receive either a one-week course of triple therapy with bismuth subcitrate, metronidazole, and tetracycline plus ranitidine or a six-week course of ranitidine 300 mg/day. After the ulcers healed, the antibiotic-treated patients were not given any medication, whereas the ranitidine-treated patients continued to receive a maintenance dose of 150 mg/day. One hundred twenty-six patients were randomized to receive anti-Helicobacter therapy and 124 patients to receive long-term ranitidine. H. pylori eradication was achieved in 98.2% in those who received triple therapy and 6.1% in those who received ranitidine (P < 0.0001). At the six-week follow-up, ulcer healing was documented in 88.2% in those who received triple therapy and 86.1% in those who received ranitidine (P = 0.639). Recurrent ulcer developed in nine of the ranitidine-treated patients and three of them presented with recurrent upper gastrointestinal bleeding. One patient in the antibiotic group developed recurrent ulcer without rebleeding (P = 0.01). It is concluded that eradication of H. pylori is sufficient for the prevention of recurrent bleeding ulcers.
Persistent Identifierhttp://hdl.handle.net/10722/163263
ISSN
2015 Impact Factor: 2.516
2015 SCImago Journal Rankings: 0.995
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorSung, JJYen_US
dc.contributor.authorLeung, WKen_US
dc.contributor.authorSuen, Ren_US
dc.contributor.authorLeung, VKSen_US
dc.contributor.authorChan, FKLen_US
dc.contributor.authorLing, TKWen_US
dc.contributor.authorLau, JYWen_US
dc.contributor.authorLee, YTen_US
dc.contributor.authorNg, EKWen_US
dc.contributor.authorCheng, AFBen_US
dc.contributor.authorChung, SCSen_US
dc.date.accessioned2012-09-05T05:29:18Z-
dc.date.available2012-09-05T05:29:18Z-
dc.date.issued1997en_US
dc.identifier.citationDigestive Diseases And Sciences, 1997, v. 42 n. 12, p. 2524-2528en_US
dc.identifier.issn0163-2116en_US
dc.identifier.urihttp://hdl.handle.net/10722/163263-
dc.description.abstractBleeding peptic ulcer is the most important cause of upper gastrointestinal bleeding. Our aim was to compare the effect of anti- Helicobacter therapy with maintenance treatment of H 2-receptor antagonist in the prevention of relapses of ulcer and bleeding. Patients with bleeding duodenal or gastric ulcers and H. pylori infection were randomized to receive either a one-week course of triple therapy with bismuth subcitrate, metronidazole, and tetracycline plus ranitidine or a six-week course of ranitidine 300 mg/day. After the ulcers healed, the antibiotic-treated patients were not given any medication, whereas the ranitidine-treated patients continued to receive a maintenance dose of 150 mg/day. One hundred twenty-six patients were randomized to receive anti-Helicobacter therapy and 124 patients to receive long-term ranitidine. H. pylori eradication was achieved in 98.2% in those who received triple therapy and 6.1% in those who received ranitidine (P < 0.0001). At the six-week follow-up, ulcer healing was documented in 88.2% in those who received triple therapy and 86.1% in those who received ranitidine (P = 0.639). Recurrent ulcer developed in nine of the ranitidine-treated patients and three of them presented with recurrent upper gastrointestinal bleeding. One patient in the antibiotic group developed recurrent ulcer without rebleeding (P = 0.01). It is concluded that eradication of H. pylori is sufficient for the prevention of recurrent bleeding ulcers.en_US
dc.languageengen_US
dc.publisherSpringer New York LLC. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0163-2116en_US
dc.relation.ispartofDigestive Diseases and Sciencesen_US
dc.subject.meshAdulten_US
dc.subject.meshAnti-Bacterial Agents - Administration & Dosageen_US
dc.subject.meshAnti-Ulcer Agents - Administration & Dosageen_US
dc.subject.meshBismuth - Administration & Dosageen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHelicobacter Infections - Complicationsen_US
dc.subject.meshHelicobacter Pylorien_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMetronidazole - Administration & Dosageen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOrganometallic Compounds - Administration & Dosageen_US
dc.subject.meshPeptic Ulcer Hemorrhage - Drug Therapyen_US
dc.subject.meshRanitidine - Administration & Dosageen_US
dc.subject.meshRecurrenceen_US
dc.subject.meshTetracycline - Administration & Dosageen_US
dc.titleOne-week antibiotics versus maintenance acid suppression therapy for Helicobacter pylori-associated peptic ulcer bleedingen_US
dc.typeArticleen_US
dc.identifier.emailLeung, WK:waikleung@hku.hken_US
dc.identifier.authorityLeung, WK=rp01479en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1023/A:1018816729449en_US
dc.identifier.pmid9440631-
dc.identifier.scopuseid_2-s2.0-6844255202en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-6844255202&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume42en_US
dc.identifier.issue12en_US
dc.identifier.spage2524en_US
dc.identifier.epage2528en_US
dc.identifier.isiWOS:000071471100023-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridSung, JJY=24473715000en_US
dc.identifier.scopusauthoridLeung, WK=7201504523en_US
dc.identifier.scopusauthoridSuen, R=18735955900en_US
dc.identifier.scopusauthoridLeung, VKS=7102336049en_US
dc.identifier.scopusauthoridChan, FKL=7202586434en_US
dc.identifier.scopusauthoridLing, TKW=13310253900en_US
dc.identifier.scopusauthoridLau, JYW=13907867100en_US
dc.identifier.scopusauthoridLee, YT=35477936800en_US
dc.identifier.scopusauthoridNg, EKW=7201647539en_US
dc.identifier.scopusauthoridCheng, AFB=7402075035en_US
dc.identifier.scopusauthoridChung, SCS=19642462800en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats